Radiosensitivity-guided personalized adaptive radiotherapy for locally advanced non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized Phase II/III trial comparing Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology (RAPART) against conventional 60 Gy radiotherapy in unresectable stage III non-small cell lung cancer. RAPART uses radiosensitivity information to tailor radiation planning and adapt treatment over time, and participants may receive standard or mixed treatment combinations according to protocol. Primary outcomes include overall survival, progression-free survival, and local progression-free survival, with inclusion of patients who have had prior surgery, chemotherapy, immunotherapy, or targeted therapy. The trial is conducted at University of Hong Kong Shenzhen Hospital and enrolls adults with ECOG 0-2.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult research participants, aged over 18 years old;
* Non small cell lung cancer that requires pathological confirmation;
* All stage 3 unresectable non-small cell lung cancer, including stage correction after MDT and stage downgrading after treatment (4 → 3), and stage upregulation due to disease progression (2 → 3);
* ECOG physical condition is 0-2;
* In addition to study participants who have not received any treatment, study participants who have undergone surgery, chemotherapy, immunotherapy, and targeted therapy are also eligible for enrollment.

Exclusion Criteria:

* Prisoners who are not convenient for close clinical follow-up;
* Study participants with contraindications to radiation therapy.

Where it's running

• University of Hong Kong Shenzhen Hospital
  Shenzhen, Guangdong, China Recruiting

Study contacts

• Study coordinator: Feng-Ming (Spring) Kong
• Email: kong0001@hku.hk
• Phone: +86 188 0755 0703

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant PD-L1/VEGF Bispecific Antibody with Chemo versus Chemo plus PD-1 Monoclonal Antibody in Locally Advanced NSCLC

  In people with locally advanced NSCLC, this study tests whether adding a PD-L1/VEGF bispecific antibody to chemotherapy before surgery improves outcomes compared with a PD-1 antibody added to chemotherapy.

  Recruiting at 2 sites Phase 3 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, China and 4 other locations · NCT07863999

• Radiation-related heart damage in locally advanced NSCLC tested with PET-CT

  This study tests whether PET-CT imaging with 18F-Flurpiridaz can detect early radiation-related heart damage in adults with locally advanced non-small cell lung cancer receiving standard chemoradiation.

  Recruiting Phase 2 Indiana University · Indianapolis, Indiana · NCT07761910

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• DS-3939a in solid tumors and non-small cell lung cancer

  This study tests DS-3939a, alone or with other anticancer drugs, in adults with solid tumors including locally advanced or metastatic NSCLC to see if it is safe and helps control the disease.

  Recruiting at 3 sites Phase 1/2 Daiichi Sankyo · Fayetteville, Arkansas and 75 other locations · NCT07739966

• Induction chemoimmunotherapy plus chemoradiotherapy and consolidation immunotherapy in unresectable locally advanced NSCLC

  This trial tests induction chemoimmunotherapy followed by chemoradiotherapy and consolidation immunotherapy in adults with unresectable stage III NSCLC to see if it can improve outcomes compared with the standard PACIFIC approach.

  Recruiting Phase 1/2 Shanghai Chest Hospital · Shanghai, Xuhui · NCT07632365

• Neoadjuvant SBRT then sintilimab with chemotherapy for N3-positive locally advanced NSCLC

  This approach tests whether focused radiation to the primary lung tumor followed by two cycles of sintilimab plus platinum-based chemotherapy before surgery can shrink N3-positive locally advanced non-small cell lung cancer and enable curative surgery.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07309952

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.